# Contact Swe Peptider — Editorial Desk

> Reach the Swe Peptider editorial desk regarding citations, corrections, or research correspondence about our Metabolic & Weight Research peptide digest.

Correspondence on citations, corrections, and newly published research — the messages this desk is most useful for.

## Editorial correspondence

Swe Peptider welcomes correspondence on the research record itself: a citation quoted inaccurately, a trial that has since published updated results, a regulatory status change, or a peer-reviewed study on MOTS-c, semaglutide, or tesamorelin that belongs on the [references page](/references). This is the category of message this desk is best positioned to act on, and each one is read. This desk does not offer a phone line or live chat; email correspondence keeps a written record that is easier to verify against a cited source, which matters more here than speed of reply.

The most actionable submissions identify the specific page, the exact passage in question, and a supporting reference — a DOI or PubMed identifier where possible — so the proposed change can be checked against its source before anything is revised.

**Editorial mailbox:** editors@swepeptider.com

## What this desk cannot do

So that no message is met with silence for the wrong reason: Swe Peptider is a literature desk, not a clinical service, and it cannot advise on or recommend human use of any compound discussed here; suggest a dose, schedule, or route of administration for any individual; judge whether a cited trial's findings apply to a specific person's situation; or help source, recommend, or locate any compound from any supplier.

Semaglutide and tesamorelin are prescription medicines available only through licensed providers for their approved indications; MOTS-c has no approved human use of any kind. Readers seeking clinical guidance should consult a licensed clinician in their jurisdiction. Responses to editorial correspondence are not guaranteed and the mailbox is monitored intermittently.

---

An independent audit of the metabolic-peptide literature that says plainly what's proven, what's preliminary, and what's still guesswork.